专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20120003204A1 COMPOSITION CONTAINING ARAZYME FOR THE PREVENTION AND TREATMENT OF CANDER 有权
标题翻译：含有ARAZYME的组合物用于预防和治疗CANDER
公开(公告)号：US20120003204A1
公开(公告)日：2012-01-05
申请号：US13225317
申请日：2011-09-02
申请人： Ho-Yong PARK , Kwang-Hee SON , Dong-Ha SHIN , Kyu-Shik JEONG
发明人： Ho-Yong PARK , Kwang-Hee SON , Dong-Ha SHIN , Kyu-Shik JEONG
IPC分类号： A61K38/48 , A61P35/00
CPC分类号： A61K38/4886 , A23C15/065 , A23G1/423 , A23G3/366 , A23G4/123 , A23G9/363 , A23L2/02 , A23L2/66 , A23L13/424 , A23L13/48 , A23L23/00 , A23L33/19
摘要： The present invention relates to a pharmaceutical composition for the prevention and treatment of cancer comprising arazyme as an active ingredient. More precisely, when arazyme produced by Aranicola proteolycius was administered to the nude mice transplanted with human lung carcinoma cell line, weight gaining, inhibition of tumor cell growth and infiltration, and down-regulations of MMP-9, NF-κB and PCNA, were observed. In addition, when arazyme was treated to human breast cancer cells (MDA-MB-231), down regulations of p21, PCNA (Proliferating Cell Nuclear Antigen), VEGF (Vascular Endothelial Growth Factor), BCl2 (B-cell CLL/lymphoma 2), p-p38, PKC (Protein Kinase C) and MMP-1 (Matrix MetalloProteinase-1) which are involved in tumor cell growth, differentiation, proliferation and metastasis, were observed along with the up-regulation of catalase which inhibits tumor development. Therefore, the arazyme can be effectively used as a pharmaceutical composition for the prevention and treatment of cancer.
摘要翻译：本发明涉及一种用于预防和治疗癌症的药物组合物，其包含作为活性成分的阿拉木霉。更准确地说，当将Aranicola proteolycius产生的arazyme给予移植有人肺癌细胞系的裸鼠，体重增加，抑制肿瘤细胞生长和浸润，以及MMP-9，NF-和Kgr B和PCNA的下调，观察。另外，当将arazyme处理到人乳腺癌细胞（MDA-MB-231）时，下调p21，PCNA（增殖细胞核抗原），VEGF（血管内皮生长因子），BCl2（B细胞CLL /淋巴瘤2 ），参与肿瘤细胞生长，分化，增殖和转移的p-p38，PKC（蛋白激酶C）和MMP-1（基质金属蛋白酶-1）以及抑制肿瘤发生的过氧化氢酶的上调。因此，可以有效地使用胂酸盐作为预防和治疗癌症的药物组合物。

2. 发明申请

US20100322917A1 PHARMACEUTICAL COMPOSITION CONTAINING ARAZYME FOR THE PREVENTION OF LIVER DYSFUNCTION 审中-公开
标题翻译：含有ARAZYME用于预防肝功能障碍的药物组合物
公开(公告)号：US20100322917A1
公开(公告)日：2010-12-23
申请号：US12521618
申请日：2006-12-28
申请人： Ho-Yong Park , Kwang-Hee Son , Dong-Ha Shin , Kyu-Shik Jeong
发明人： Ho-Yong Park , Kwang-Hee Son , Dong-Ha Shin , Kyu-Shik Jeong
IPC分类号： A61K38/48 , A61P1/16 , A61P35/00 , C12N9/52
CPC分类号： A61K38/4886 , A23L33/10 , A23L33/135
摘要： The present invention relates to a pharmaceutical composition for the prevention of liver dysfunction which contains arazyme as an active ingredient, more precisely a pharmaceutical composition for the prevention of liver dysfunction which contains arazyme produced by Aranicola proteolyticus. The arazyme of the present invention inhibits apoptosis in injured liver cells, increases SMP30 expression, inhibits P-smad3 expression and protects liver by inhibiting liver injury around central vein region. Therefore, the arazyme of the invention can be effectively used as a pharmaceutical composition for the prevention of liver dysfunction.
摘要翻译：本发明涉及一种用于预防肝功能障碍的药物组合物，其含有作为活性成分的阿拉木霉，更准确地说，涉及含有由Aranicola proteolyticus产生的arazyme的用于预防肝功能障碍的药物组合物。本发明的arazyme抑制受损肝细胞凋亡，增加SMP30表达，抑制P-smad3表达，通过抑制中心静脉区域周围的肝损伤来保护肝脏。因此，本发明的芳脒可以有效地用作预防肝功能障碍的药物组合物。

3. 发明申请

US20090317374A1 COMPOSITION CONTAINING ARAZYME FOR THE PREVENTION AND TREATMENT OF CANCER 审中-公开
标题翻译：含有ARAZYME用于预防和治疗癌症的组合物
公开(公告)号：US20090317374A1
公开(公告)日：2009-12-24
申请号：US12521676
申请日：2007-12-28
申请人： Ho-Yong Park , Kwang-Hee Son , Dong-Ha Shin , Kyu-Shik Jeong
发明人： Ho-Yong Park , Kwang-Hee Son , Dong-Ha Shin , Kyu-Shik Jeong
IPC分类号： A61K38/48 , A61P35/00
CPC分类号： A61K38/4886 , A23C15/065 , A23G1/423 , A23G3/366 , A23G4/123 , A23G9/363 , A23L2/02 , A23L2/66 , A23L13/424 , A23L13/48 , A23L23/00 , A23L33/19
摘要： The present invention relates to a pharmaceutical composition for the prevention and treatment of cancer comprising arazyme as an active ingredient. More precisely, when arazyme produced by Aranicola proteolycius was administered to the nude mice transplanted with human lung carcinoma cell line, weight gaining, inhibition of tumor cell growth and infiltration, and down-regulations of MMP-9, NF-κB and PCNA, were observed. In addition, when arazyme was treated to human breast cancer cells (MDA-MB-231), down regulations of p21, PCNA (Proliferating Cell Nuclear Antigen), VEGF (Vascular Endothelial Growth Factor), BCl2 (B-cell CLL/lymphoma 2), p-p38, PKC (Protein Kinase C) and MMP-1 (Matrix MetalloProteinase-1) which are involved in tumor cell growth, differentiation, proliferation and metastasis, were observed along with the up-regulation of catalase which inhibits tumor development. Therefore, the arazyme can be effectively used as a pharmaceutical composition for the prevention and treatment of cancer.
摘要翻译：本发明涉及一种用于预防和治疗癌症的药物组合物，其包含作为活性成分的胂酸盐。更准确地说，当将Aranicola proteolycius产生的arazyme给予移植有人肺癌细胞系的裸鼠时，体重增加，抑制肿瘤细胞生长和浸润以及MMP-9，NF-κB和PCNA的下调均为观察到的。另外，当将arazyme处理到人乳腺癌细胞（MDA-MB-231）时，下调p21，PCNA（增殖细胞核抗原），VEGF（血管内皮生长因子），BCl2（B细胞CLL /淋巴瘤2 ），参与肿瘤细胞生长，分化，增殖和转移的p-p38，PKC（蛋白激酶C）和MMP-1（基质金属蛋白酶-1）以及抑制肿瘤发生的过氧化氢酶的上调。因此，可以有效地使用胂酸盐作为预防和治疗癌症的药物组合物。

4. 发明申请

US20120003205A1 PHARMACEUTICAL COMPOSITION CONTAINING ARAZYME FOR THE PREVENTION OF LIVER DYSFUNCTION 有权
标题翻译：含有ARAZYME用于预防肝功能障碍的药物组合物
公开(公告)号：US20120003205A1
公开(公告)日：2012-01-05
申请号：US13234847
申请日：2011-09-16
申请人： Ho-Yong PARK , Kwang-Hee SON , Dong-Ha SHIN , Kyu-Shik JEONG
发明人： Ho-Yong PARK , Kwang-Hee SON , Dong-Ha SHIN , Kyu-Shik JEONG
IPC分类号： A61K38/48 , A61P31/14 , A61P1/16
CPC分类号： A61K38/4886 , A23L33/10 , A23L33/135
摘要： The present invention relates to a pharmaceutical composition for the prevention of liver dysfunction which contains arazyme as an active ingredient, more precisely a pharmaceutical composition for treating liver dysfunction which contains arazyme produced by Aranicola proteolyticus. The arazyme of the present invention inhibits apoptosis in injured liver cells, increases SMP30 expression, inhibits P-smad3 expression and protects liver by inhibiting liver injury around central vein region. Therefore, the arazyme of the invention can be effectively used as a pharmaceutical composition for the prevention of liver dysfunction.
摘要翻译：本发明涉及一种用于预防肝功能障碍的药物组合物，其包含作为活性成分的阿拉木霉，更准确地说，涉及一种用于治疗肝功能障碍的药物组合物，其含有由Aranicola proteolyticus产生的arazyme。本发明的arazyme抑制受损肝细胞凋亡，增加SMP30表达，抑制P-smad3表达，通过抑制中心静脉区域周围的肝损伤来保护肝脏。因此，本发明的芳脒可以有效地用作预防肝功能障碍的药物组合物。

5. 发明申请

US20100278806A1 Composition Containing Arazyme for the Prevention and Treatment of Arthritis 审中-公开
标题翻译：包含关于预防和治疗关节炎的疯狂的组合
公开(公告)号：US20100278806A1
公开(公告)日：2010-11-04
申请号：US12812388
申请日：2009-01-09
申请人： Ho-Yong Park , Kwang-Hee Son , Dong-Ha Shin , Kyu-Shik Jeong
发明人： Ho-Yong Park , Kwang-Hee Son , Dong-Ha Shin , Kyu-Shik Jeong
IPC分类号： A61K38/48 , A61P19/02
CPC分类号： A61K38/4886
摘要： Disclosed herein is a composition containing arazyme as an active ingredient for prevention and treatment of arthritis. More specifically, arazyme produced from Aranicola proteolyticus of the present invention may be useful as a composition for prevention and treatment of arthritis by inhibiting the expression of TNF-α which is an inflammation-inducing factor and preventing the loss of proteoglycan and collagen from joint cartilage to inhibit the progression of arthritis and protect joints.
摘要翻译：本文公开了含有作为预防和治疗关节炎的活性成分的阿拉木霉的组合物。更具体地说，本发明的由Aranicola proteolyticus产生的arazyme可用作通过抑制作为炎性诱导因子的TNF-α的表达来预防和治疗关节炎的组合物，并防止蛋白聚糖和胶原从关节软骨中的损失抑制关节炎的进展并保护关节。

6. 发明授权

US08367060B2 Pharmaceutical composition containing arazyme for the prevention of liver dysfunction 有权
标题翻译：含有arazyme用于预防肝功能障碍的药物组合物
公开(公告)号：US08367060B2
公开(公告)日：2013-02-05
申请号：US13234847
申请日：2011-09-16
申请人： Ho-Yong Park , Kwang-Hee Son , Dong-Ha Shin , Kyu-Shik Jeong
发明人： Ho-Yong Park , Kwang-Hee Son , Dong-Ha Shin , Kyu-Shik Jeong
IPC分类号： A61K38/48
CPC分类号： A61K38/4886 , A23L33/10 , A23L33/135
摘要： The present invention relates to a composition and a method for the treatment of liver dysfunction which contains administration of a composition containing arazyme as an active ingredient, more precisely arazyme produced by Aranicola proteolyticus. The arazyme of the present invention inhibits apoptosis in injured liver cells, increases SMP30 expression, inhibits P-smad3 expression and protects the liver by inhibiting liver injury around the central vein region. Therefore, the arazyme of the invention can be effectively used as a composition for the treatment of liver dysfunction.
摘要翻译：本发明涉及一种治疗肝功能障碍的组合物和方法，其包含施用含有阿拉木霉作为活性成分的组合物，更准确地说是由Aranicola proteolyticus产生的arazyme。本发明的arazyme抑制受损肝细胞凋亡，增加SMP30表达，抑制P-smad3表达，并通过抑制中心静脉区周围的肝损伤来保护肝脏。因此，本发明的胂酸盐可以有效地用作治疗肝功能障碍的组合物。

7. 发明授权

US07083968B2 Microorganism of serratia family, isolation method and the preparation method of lignin lyases using this 有权
标题翻译：沙雷氏菌家族的微生物，分离方法和木质素裂解酶的制备方法
公开(公告)号：US07083968B2
公开(公告)日：2006-08-01
申请号：US10481233
申请日：2001-07-31
申请人： Ho Yong Park , Ki Duk Kim , Dong Ha Shin
发明人： Ho Yong Park , Ki Duk Kim , Dong Ha Shin
IPC分类号： C12N1/12
CPC分类号： C12Y110/03002 , C12N1/20 , C12N9/0061 , C12N9/0065 , C12R1/43 , C12Y111/01013 , C12Y111/01014
摘要： The present invention relates to a novel microbe belonging to Serratia family, its isolation method and the preparation method using it. More particularly, the present invention relates to a microorganism of Serratia family producing laccase, lignin peroxidase and Mn-dependent-peroxidase which are the kinds of lignin lyases, and a method for separating the microbe from insect gut, as well as a method for preparing laccase, lignin peroxidase and Mn-dependent-peroxidase. The microorganism of the present invention can be used not only in the treatment of industrial sewage and harmful environmental substance but also in oil degradation, in biological bleaching of pulp since it can produce lignin lyases. More over, the microbe can also be used effectively in industry of preparing fuel, forage and other chemicals through lignin degradation.
摘要翻译：本发明涉及属于沙雷氏菌家族的新型微生物，其分离方法及其制备方法。更具体地说，本发明涉及一种生产漆酶的沙雷氏菌家族微生物，木素过氧化物酶和木质素过氧化物酶，它们是木质素裂解酶的种类，以及从昆虫肠中分离微生物的方法以及一种制备方法漆酶，木质素过氧化物酶和Mn依赖性过氧化物酶。本发明的微生物不仅可用于工业污水和有害环境物质的处理，而且可用于油类生物漂白中的油分解，因为它可以生产木质素裂解酶。此外，微生物也可以有效地用于通过木质素降解制备燃料，饲料和其他化学品的工业。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式